Gold(III) complexes with thiosemicarbazonate ligands as potential anticancer agents: Cytotoxicity and interactions with biomolecular targets

被引:14
|
作者
Possato, Bruna [1 ]
Dalmolin, Luciana Falcco [1 ]
Pereira, Luiz Miguel [1 ]
Alves, Jacqueline Querino [2 ]
Silva, Raphael Tristao Cruvinel [3 ]
Gelamo, Rogerio Valentim [4 ]
Yatsuda, Ana Patricia [1 ]
Lopez, Renata Fonseca Vianna [1 ]
de Albuquerque, Sergio [1 ]
Leite, Natalia Bueno [3 ]
Maia, Pedro Ivo da Silva [3 ]
机构
[1] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Ribeirao Preto, Brazil
[2] Prefeitura Municipal Ribeirao Preto, Secretaria Educ, Ribeirao Preto, Brazil
[3] Univ Fed Triangulo Mineiro, Nucl Desenvolvimento Compostos Bioat NDCBio, Uberaba, Brazil
[4] Univ Fed Triangulo Mineiro, Inst Ciencias Tecnol & Exatas, Uberaba, Brazil
基金
巴西圣保罗研究基金会;
关键词
Cancer; DNA; Cell membrane model; Transition metal complexes; Albumin; Thiosemicarbazones; HUMAN SERUM-ALBUMIN; CISPLATIN; FLUORESCENCE; BINDING; DNA;
D O I
10.1016/j.ejps.2021.105834
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gold(III) complexes have been studied for the past years due to their anticancer properties and great affinity to biotargets, such as enzymes and proteins, which support their pharmacological applications. Within this scope, in this work the antiproliferative activities of two Au(III)-thiosemicarbazonate complexes, [AuClL1] (1, L1: (E,Z)-Nethyl-N'-(3-nitroso-kN)butan-2-ylidene)carbamohydrazonothioato-k2N2,S) and [Au(Hdamp)L2]Cl (2, L2: N-(N", N"-diethylaminothiocarbonyl)-N'(N"', N"'-dimethylcarbothioamide)benzamidineto-kN,k2S and Hdamp: 2-(N, N-dimethylaminomethyl)-phenyl-C1), and their affinities to possible biological targets were investigated. Three different tumor cell lines were used to perform the cytotoxicity assays, including one cisplatin-resistant model, and the results showed lower EC50 for 1 over 2 in every case: B16F10 (4.1 mu M and 15.6 mu M), A431 (4.0 mu M and >50 mu M) and OVCAR3 (4.2 mu M and 24.5 mu M). However, a lower toxicity to fibroblast 3T3 cell line was observed for 2 (30.58 mu M) when compared to 1 (7.17 mu M), resulting in comparable therapeutic indexes. Both complexes presented strong affinity to HSA: they distorted the secondary structure of the protein, as verified by circular dichroism, but 1 additionally presented the apparent fluorescence quenching constant (Kapp) ten times greater than 2, which was probably due to the fact of 1 being able to denature HSA. The ethidium bromide displacement assay showed that neither 1 nor 2 are strong DNA intercalators, which is in agreement with what was observed through the UV-vis titration. In both cases, the 260 nm band presented hyperchromism, which can indicate ionic interactions or DNA damage. In fact, 1 was able to damage the pGEM plasmid, similarly to cisplatin, as verified by agarose gel electrophoresis and Atomic Force Microscopy. Biophysical studies in cancer cells model membranes were also performed in order to investigate the interaction of the gold complexes to lipid bilayers and revealed that the compounds interact with the membranes by exhibiting partition coefficients of 103 order of magnitude. Overall, both complexes were found to be promising candidates for the development of a future anticancer drug against low sensitive or cisplatin resistant tumors.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Gold(III) heteroleptic complexes with SNS-thiosemicarbazonate ligands as cytotoxic agents: Experimental and computational insights into the mechanism of action
    da Silva, Amandha Kaiser
    Santos, Mal Mateus
    Candido, Pamela Aparecida
    de Oliveira Lopes, Erica
    Pavan, Fernando Rogerio
    Carneiro, Zumira Aparecida
    da Silva, Marcos Vincius
    de Oliveira, Carlo Jose Freire
    Batista, Alzir Azevedo
    de Oliveira, Ronaldo Junio
    Deflon, Victor Marcelo
    da Silva Maia, Pedro Ivo
    POLYHEDRON, 2022, 219
  • [2] Gold (III) compounds as potential antitumor agents: Cytotoxicity and DNA binding of some selected gold (III) complexes
    Carotti, S
    Guerri, A
    Mazzei, T
    Messori, L
    Mini, E
    Orioli, P
    ANNALS OF ONCOLOGY, 1998, 9 : 29 - 29
  • [3] The role of tridentate ligands on the redox stability of anticancer gold (III) complexes
    Delgado, Giset Y. Sanchez
    Ferreira, Frederico Henrique do C.
    Paschoal, Diego F. S.
    Dos Santos, Helio F.
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2022, 236
  • [4] Gold(III) tetraarylporphyrin phosphonate derivatives as potential anticancer agents
    Chen, Huasheng
    Li, Jun
    Shen, Tingting
    Li, Yan
    Liu, Juanjuan
    Liu, Jinliang
    Xu, Aihua
    Wang, Cunde
    JOURNAL OF CHEMICAL RESEARCH, 2012, (09) : 501 - 505
  • [5] Gold(III) compounds as potential antitumor agents: cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes
    Carotti, S
    Guerri, A
    Mazzei, T
    Messori, L
    Mini, E
    Orioli, P
    INORGANICA CHIMICA ACTA, 1998, 281 (01) : 90 - 94
  • [6] Advances in alkynyl gold complexes for use as potential anticancer agents
    Yang, Zhibin
    Jiang, Guizhi
    Xu, Zhongren
    Zhao, Sai
    Liu, Wukun
    COORDINATION CHEMISTRY REVIEWS, 2020, 423
  • [7] Bioengineered lipophilic Ru(III) complexes as potential anticancer agents
    Riccardi, Claudia
    Piccolo, Marialuisa
    Ferraro, Maria Grazia
    Graziano, Raffaele
    Musumeci, Domenica
    Trifuoggi, Marco
    Irace, Carlo
    Montesarchio, Daniela
    BIOMATERIALS ADVANCES, 2022, 139
  • [8] Deubiquitinases as Anticancer Targets of Gold Complexes
    Zou, Taotao
    Zhang, Jing-Jing
    Cao, Bei
    Tong, Ka-Chung
    Lok, Chun-Nam
    Che, Chi-Ming
    ISRAEL JOURNAL OF CHEMISTRY, 2016, 56 (9-10) : 825 - 833
  • [9] Current Development of Metal Complexes with Diamine Ligands as Potential Anticancer Agents
    Misirlic-Dencic, Sonja T.
    Poljarevic, Jelena
    Isakovic, Andjelka M.
    Sabo, Tibor
    Markovic, Ivanka
    Trajkovic, Vladimir
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (03) : 380 - 410
  • [10] Newly synthesized Zinc/Gold and Zinc/Silver complexes with Schiff-base ligands as potential anticancer agents
    Alexandrova, R.
    Zhivkova, T.
    Abudalleh, A.
    Dyakova, L.
    Dinev, D.
    Mitrenga, P.
    Ivanov, D.
    Toshkova, R.
    Gavrilov, I.
    Georgieva, M.
    Miloshev, G.
    Culita, D.
    Marinescu, G.
    Patron, L.
    Kalfin, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S17 - S18